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The present study was conducted to examine the relationship between plasma concen-
trations of testosterone, insulin-like growth factor I (IGF-I) and IGF-binding proteins(IGFBPs) during puberty, in male calves treated with GnRH or testosterone propionate.
Twelve male Holstein calves (10 weeks old) were assigned to the control group (n = 6), the
GnRH-treated group (n = 3) or the testosterone-treated group (n
=
3). For 8 weeks, the
GnRH-treated group received a single i.v. injection of GnRH (0.5 \g=m\gkg \m=-\1body mass) each
day while the testosterone-treated group received an i.m. injection of testosterone
propionate (0.5 mg kg \m=-\1body mass) twice a day. The calves were studied until they were
200 days old. Hormone treatments were stopped one month after puberty was reached in
the control group. Blood samples were collected every 30 min for 8 h every third day.
Hormone concentrations were determined by radioimmunoassay. Western ligand blotting
and immunoblotting, using monoclonal antibodies against IGFBP-2 and IGFBP-3, were used
to characterize the IGF-binding proteins. In the control group, puberty occurred at about
120 days of age and was associated with an increase in concentrations of testosterone, IGF-I
and IGFBP-3 and a decrease in concentration of IGFBP-2. In the GnRH-treated group,
plasma testosterone remained low until 8 weeks after establishment of puberty in the
control group (4 weeks after the end of treatment). In the testosterone-treated group,
testosterone was high during the treatment period and then decreased to prepubertal values
when treatment was stopped. Testosterone values increased again to reach postpubertal
values 5 weeks after the end of hormone treatment. Nevertheless, independent of
testosterone status, the profile of IGF-I and the IGFBPs in the GnRH- and testosterone\x=req-\
treated groups were parallel to that reported for the control group with the transition from
prepubertal to adult values at about 120 days of age. In conclusion, concentrations of
testosterone, IGF-I and IGFBP-3 increase together, but probably independently, during the
onset of puberty in male calves.
Introduction
The onset of puberty has been shown to be a complex
synergism between sex steroids and insulin-like growth factor I(IGF-I) in humans (Metzger et al, 1994), sheep (Lord et al,
1991) and in cattle (Renaville et al, 1993). During this period,
testosterone is released episodically and plasma concentrations
of IGF-I increase strikingly, concomitant with an increase in
mean plasma concentration of testosterone. A positive corre¬
lation was noted between the concentrations of these two
hormones for bull calves during this physiological step(Renaville et al, 1993). Moreover, as in humans (Smith et al,
1993), baboons (Crawford et al, 1994) and pigs (Lee et al,
1991a), in cattle, the transition from prepubertal to mature
male is characterized by a marked increase in IGFBP-3
concentrations (Renaville et al, 1993).
However, information on the possible link between IGF-I
and testosterone synthesis during this physiological step is
contradictory. Jasper (1985), Harris et al (1985) and Attie et al
(1990), in humans, and Lee el al (1991b), in cattle, reported that
sex steroids stimulate IGF-I concentrations directly at the time
of puberty, while Crawford et al (1993) concluded that the
pubertal IGF-I surge in mice does not require androgens in
either the pre- or postpubertal periods. In addition, Godfrey
et al (1992) demonstrated that treatment with testosterone
propionate delays puberty and endogenous pulsatile release
of testosterone in bull calves, while Ronayme et al (1993)
described an increase in testosterone concentrations in
prepubertal bulls treated continuously with GnRH.
In the study described here, prepubertal bull calves were
treated with testosterone propionate or GnRH to determine
whether IGF-I is dependent on the androgen surge at the onset
of puberty.Received 21 June 1995.
Materials and Methods
Animals
Twelve, spring-born (identical calving day), Holstein male
calves (10 weeks old) were assigned to either the control group(n = 6) or groups treated with either GnRH (n = 3) or testos¬
terone propionate (n = 3). The 6x3x3 experimental design
used in the present study is justified by the fact that all data
have been evaluated by comparison with the age of the onset
of pulsatile testosterone release in the control group. The large
number of animals in the control group was judged necessary
to characterize this physiological stage exactly.
Animals were fed with grass hay twice a day and a
commercial allmash containing 130 g crude protein kg ~ 1. Feed
intake was controlled so that body mass gain was about
950 g day ~ ; water was supplied ad libitum. All animals were
kept in identical conditions. Daily room temperature (18°C) and
daylength (16 h light:8 h dark) were constant. Initial mean live
masses were 74.4 ± 4.8 kg for the control group, 75.9 ± 3.2 kg
for the GnRH-treated group and 73.1 ± 5.9 kg for the
testosterone-treated group.
Experimental design
For a period of 8 weeks, the GnRH-treated group received a
daily i.v. injection of GnRH (0.5 µg kg- body mass; Sigma,
St Louis, MO) in 0.5 ml saline and the testosterone-treated
group was given an i.m. injection of testosterone propionate(0.5 mg kg ~
.
body mass; Sigma) in 0.5 ml saline twice a day.
Control calves received an i.m. injection of saline (0.5 ml) daily.
Animals were studied between 70 and 200 days of age (day
0 = birth). Hormone treatments were stopped one month after
puberty was achieved in the control group. Puberty was taken
as the time when more than two successive values of testos¬
terone were greater than 2 ng ml ~  (Renaville et al, 1993).
Blood samples (5 ml) were taken from the jugular vein via a
polyurethane catheter into heparinized tubes at 30 min inter¬
vals from 08:00 h to 17:00 h every third day. Samples were
stored immediately at 4°C and then centrifuged at 1800 g for
10 min. Plasma was separated and stored at
—
20°C until it was
used in the hormone and binding-protein assays.
Iodination procedure
The recombinant bovine IGF-I (rbIGF-1; batch GTS-1) used
as iodinated tracer (in radioimmunoassay and western ligand
blotting) and as standard (in radioimmunoassay) was kindly
donated by Monsanto (St Louis, MO). The hormone was
labelled with Na[ I] by the chloramine  method (Parker,
1990). I25I-labelled rbIGF-I was separated from free iodine
using a Centricon-3 microconcentrator as recommended by the
manufacturer (Amicon Division, Beverly, MA). The specific
activity was 70 pCi pg ~ .
Tritiated testosterone ([1,2,6,7- Hjtestosterone, batch TRK
402, specific activity 80-105 Ci mmol ~ J) was purchased from
Amersham International (Amersham, Bucks).
Production of monoclonal antibodies against bovine IGF binding
protein (IGFBP) -2 and -3
Anti-bovine IGFBP-2 and IGFBP-3 monoclonal antibodies
were produced in our laboratory (Porteteile et al, 1995). Briefly,
ten-week-old female BALB/c mice were immunized with
100 µg recombinant fusion protein bovine IGFBP-2 (or -3)-
maltose binding protein (MBP) in incomplete Freund's adju¬
vant (0.10 ml total volume) equally distributed into the rear
footpads. Fourteen days after immunization, mice were bled as
recommended by Mirza et al (1987) and the draining lymph
nodes (popliteal and inguinal) were removed and pooled for
fusion as described by Brück et al. (1982) with the modification
that NSO murine cells were used as myeloma partner.
Specific antibody-producing hybridomas were identified by
differential indirect enzyme-linked immunosorbent assays(ELISA) tests using recombinant proteins IGFBP-MBP or MBP
adsorbed onto the wells (Porteteile et al, 1989). Positive
hybridomas were cloned twice in soft agar, grown on Pristane-
primed BALB/c mice and then purified by ion-exchange
chromatography. In the present study, the 7B5 anti-IGFBP-3(isotype IgGl) monoclonal antibody and the 8G10 anti-
IGFBP-2 (isotype IgGl) monoclonal antibody were used in the
immunoblot studies.
Hormone determination
Testosterone was determined by radioimmunoassay as
described by Renaville et al (1983). The minimum detectable
dose of testosterone was 0.1 ng ml-1. The intra- and inter¬
assay coefficients of variation were 4.8% and 10.7%, respec¬
tively, for the low standard concentration (0.8 ng ml~ ) and
2.1% and 6.1%, respectively, for high standard concentration(10 ng ml-1).
The radioimmunoassay for IGF-I in bull plasma was per¬
formed according to the method described by Lemal et al(1989) and adapted by Renaville et al (1993). In this method, as
reported by Breier et al (1991), a cryoprecipitation step is used
to eliminate aggregated proteins in plasma extracts. Briefly,
after acid-ethanol extraction (87.5% ethanol and 12.5% HC1
mol 1
~
v/v), an aliquot of the supernatant was neutralized
with 0.855 mol Tris base 1~ ' at a ratio of 5:2. The samples
were stored at
—
20°C for 1 h and then centrifuged at 3000 g
for 30 min at 4°C. The supernatant was decanted into fresh test
tubes and used in the radioimmunoassay. The minimum
detectable dose of IGF-I was 1 ng ml ~ . Intra- and interassay
coefficients of variation were 12% and 16%, respectively, for
the low standard concentration (25 ng ml-1) and 6.5% and
9%, respectively, for the high standard concentration(250 ng ml " x).
Western ligand blotting
Western ligand blotting was performed to evaluate plasma
IGFBPs following the method described by Renaville et al(1993). Briefly, 1 µ of SDS-denatured plasma was applied to a
4% stacking gel and electrophoresis was performed through a
12.5% polyacrylamide gel. Prestained I4C-labelled molecular
weight markers (Amersham) were run in parallel lanes. The gels
were then soaked in Towbin buffer (25 mmol Tris 1
~
\
192 mmol glycine 1 \ 20% (v/v) methanol, pH 8.3) and
proteins were blotted onto nitrocellulose sheets (Hybond-C,
Amersham). Electrophoresis and electrotransfer were per¬
formed using the Mini-Protean II system (Bio-Rad, Richmond,
CA). After saturation, membranes were incubated with
I25I-labelled rbIGF-I (4000 c.p.m. cm " 2 blot) overnight at 4°C.
The membranes were then washed, air-dried and exposed to
Kodak X-Omat AR films (Rochester, NY) for 2-4 days at
-
70°C.
Autoradiograms were scanned using a Sharp JX 325 scanner
and band intensities were analysed with imagemaster id soft¬
ware (Pharmacia, Uppsala). A plasma pool was used as internal
standard.
Immunoblotting
Plasma samples (1.5 µ ) were denatured by SDS with di-
thiothreitol as reducing agent and then applied to a 4%
stacking gel; electrophoresis was performed through a 12.5%
SDS-polyacrylamide gel, and blotted onto Immobilon sheet.
Electrophoresis and electrotransfer were performed using the
Mini-Protean II System (Bio-Rad).
Membranes were saturated for 1 h at room temperature with
a 10% defatted milk solution in Tris saline buffer (10 mmol
Tris-HCl 1
"
\ 150 mmol NaCl  \ pH 7.4), and then incu¬
bated overnight at 4°C with monoclonal antibody (mAb) 7B5(2.4 pg mP1) or mAb 8G10 (2.1 pg ml" :) diluted in Tris
saline buffer containing 0.1% (v/v) Tween 20. Membranes were
washed three times in Tris saline buffer containing 0.1% Tween
20 (v/v), followed by incubation for 1 h at room temperature
with alkaline phosphatase coupled goat-anti-mouse antibody(0.133 pg ml" ; Promega, Leiden) in Tris saline buffer contain¬
ing 0.1% Tween 20 (v/v). Membranes were washed four times
in Tris saline buffer containing 0.1% Tween 20, and alkaline-
phosphatase activity was revealed using NBT/BCIP substrate(KPL, Gaithersburg, MD).
Immunoblot membranes were scanned using a Sharp JX 325
scanner and band intensities were analysed with imagemaster
id software. A plasma pool was used as the internal
standard.
Statistical analyses
Values are presented as means ± sd. Between-group signifi¬
cance for parameters was assessed by analysis of variance using
the GLM procedure of sas software (SAS®, 1991). The
following model was used:
 # = µ+ , +
 ,
+ (  ),> + ^
where Y¡jk = observations for dependent variables of treatment
i during period j on animal k; µ = overall mean; T¡ = treatment
effect (i = 1, 2, 3); P¡ = period effect ( j = 1, 2, 3.41, 42, 43);(  )1( = fixed effect associated with interaction between treat¬
ment i at period ;',· and eik = random residual effect for the ith
treatment and the jth period.
Significant differences among means were determined by the
F test at 5% probability.
Results
Changes in the concentrations of hormones during puberty
In the control group, mean plasma concentrations of testos¬
terone increased significantly (P < 0.001) from 105 ± 5 days
old (mean value: 0.7 + 0.2 ng ml"1) to 120 ± 10 days(2.1 ± 0.3 ng ml ~ J) (Fig. la). During this period, release of the
hormone became pulsatile (values ranging from 0.2 ±0.1 ng
ml
~
1 to 4.3 ± 1.9 ng ml ~ :), indicating that puberty had been
reached. Mean concentrations of testosterone then increased
progressively to day 160 (mean value: 3.1 ± 0.8 ng ml~ :), after
which they remained relatively constant up to the end of the
experimental period.
Hormone treatments had different effects on plasma testos¬
terone concentrations. Injections of testosterone propionate
immediately induced a significant (P < 0.001) increase in plasma
testosterone; however, there was no daily episodic release, and
concentrations remained higher (7—9 ng ml ~ ;  < 0.001) than
in the control group during the treatment period (Fig. la).
When testosterone treatment was discontinued (day 150; one
month after the onset of puberty in the control group), mean
plasma concentrations fell to prepubertal values (0.5 ± 0.2 ng
ml
~
) in one week, and were lower than in the control group(P< 0.001) (Fig. la). It was only at 187 ± 5 days (33 ± 7 days
after the end of treatment) that a pulsatile release of endog¬
enous testosterone was osberved in this group and mean daily
concentrations reached similar values to those in the controls.
In the GnRH-treated group, a daily injection of GnRH affected
the release of testosterone. From day 70 to day 110, mean
values were low (range values: 0.3—0.7 ng ml-1) and no
significant differences were observed with the control group.
After day 110, while testosterone concentrations in the control
group increased, values in the GnRH group, remained low until
day 163 ± 6 (3.1 ± 0.8 ng ml~~ in the control group compared
with 0.2 ± 0.1 ng ml" 1 in the GnRH group;  < 0.001), from
which time concentrations slowly increased, finally exhibiting
pulsatile release and similar mean values to the control group(P>0.05) at day 181 ±4.
During the experimental period, mean plasma concentrations
of IGF-I exhibited a similar pattern in all groups. From day 70
to day 110, mean plasma IGFT values were relatively constant
and no significant differences (P>0.05) were observed
between the experimental groups and the control group,
with mean values for the period as follows: control group:
93 + 14 ng ml"1; testosterone-treated group: 76±17ng
ml" : and GnRH-treated group: 71 ± 19 ng ml" 1 (Fig. lb).
From day 110 to day 130, a sharp increase (P < 0.001) in
plasma concentrations was observed in all groups:
182 ± 35 ng ml ~ : in the control group; 156 ± 24 ng ml ~ : in
the testosterone-treated group and 163 + 34 ng ml ~ in the
GnRH-treated group. IGF-I concentrations in the control
group then continued to increase, to reach values of about
250-300 ng ml ~ l at the end of the experiment. In the two
treatment groups, IGF-I concentrations increased more slowly
and were below values for the control group between days
145 and 155 (P < 0.01). A second increase was observed
between days 160 and 185 in the two treatment groups
when values similar to those seen in the controls were
reached.
Fig. 1. Mean plasma concentrations of (a) testosterone and (b) insulin-like growth factor I in (O) control, (·)
testosterone propionate-treated and ( ) GnRH-treated bulls during the onset of puberty. (D) The period of
treatment. Arrows indicate the onset of puberty in each group: (O) control; (·) testosterone propionate-treated
and ( ) GnRH-treated groups.
Western ligand blotting of IGFBPs
Western ligand blotting of bovine plasma revealed four
distinct bands that specifically bound 125I-labelled IGF-I. Their
molecular masses were, respectively, 45-54, 38, 28 and 24 kDa.
In the control group, the onset of puberty was characterized by
an increase from day 100 (0.69 + 0.14 units) to day 150(1.72 ±0.21 units) (P < 0.001) in the intensity of the doublet
45—54 kDa band, which was identified as IGFBP-3, after
which it remained constant until the end of the experiment(Fig. 2a). The intensity of the IGFBP-2 (38 kDa) band was
markedly reduced from day 120 (0.67 ± 0.18 units) to day 160(0.17 ±0.08 units) (P < 0.001) and remained low until the
end of the experiment (Fig. 2b). During this period, no
variations were observed for the 28 kDa and 24 kDa bands,
Fig. 2. Mean plasma concentration of (a) insulin-like growth factor-binding protein-3 (IGFBP-3) and (b) IGFBP-2
in (O) control, (·) testosterone propionate-treated and ( ) GnRH-treated groups during the onset of puberty.( ): The period of treatment. Arrows indicate the onset of puberty in each group: (O) control; (·) testosteronepropionate-treated and ( ) GnRH-treated groups.
corresponding to IGFBP-1 and IGFBP-4, respectively (data not
shown).
Daily injections of testosterone propionate or GnRH had no
effect on mean plasma concentrations of IGFBP-2 and IGFBP-3.
Indeed, the profile of these two proteins was similar to that
reported for the control group, with a progressive increase in
IGFBP-3 from about day 100 and a sharp decrease in IGFBP-2
after day 120 in both groups. No significant difference
(P> 0.05) was observed on any day of collection between the
values in control and treated groups.
Immunoblotting of IGFBP-2 and IGFBPS
The immunoblot method, using monoclonal antibodies
against bovine IGFBP-2 and IGFBP-3, showed a similar pattern
Fig. 3. (a) Plasma insulin-like growth factor binding protein-3 (IGFBP-3) and (b) IGFBP-2 in an individual
bull calf 3 weeks before (lanes 1-3) and three weeks after (lanes 5-7) puberty. Lane 4 represents the week
during which the animal attained puberty (pulsatile release of testosterone). The proteins were revealed
using monoclonal antibodies against bovine IGFBP-3 or IGFBP-2.
for these two proteins throughout the experimental period(Fig. 3) and was in agreement with data obtained using western
ligand blotting.
Discussion
The study reported here was conducted to define the relation¬
ship between plasma concentrations of testosterone and IGF-I
during puberty, by treating male calves with GnRH or testo¬
sterone propionate. In the control group, the onset of puberty
in bull calves was identified by concomitant rises of plasma
concentrations of testosterone and IGF-I, as described by
Ronge and Blum (1989a, b) and Renaville et al (1993). It has
been suggested by previous studies, particularly in humans(Kerrigan and Rogol, 1992; Zachmann, 1992; Metzger et al,
1994), that these coordinated hormonal increases are driven by
growth hormone. Indeed, data from the control group in the
present study suggests that the puberty-associated increase in
plasma concentrations of IGF-I could result from the stimula¬
tory effect of testosterone on the somatotrophic axis, indirectly
mediated via the oestrogen receptor after the aromatization of
testosterone to oestradiol. Schwarz et al. (1992) reported that
gonadectomy in cattle causes a fall in plasma concentrations of
GH, testosterone and IGF-I and Metzer and Kerrigan (1994)
showed that blocking the oestrogen receptor with tamoxifen
results in decreased 24 h mean serum GH and plasma IGF-I in
humans. However, Metzger et al. (1994) concluded that it is
difficult to differentiate between the testosterone effects
because the hormone can act either directly through the
androgen receptor or indirectly through the oestrogen receptor
once it is aromatized to oestrogen.
Under the experimental conditions in the present study,
hormonal treatment of prepubertal bulls inhibited endogenous
testosterone production. The partial suppression of gonadal
steroidogenesis by GnRH (a prepubertal level was maintained)
observed in this study are in agreement with previous reports
in men (Harris et al, 1985; Styne et al, 1985), rams (Lincoln
et al, 1986) and stags (Lincoln, 1987) but are in conflict with
studies in mature bulls (Rechenberg et al, 1986; Ronayme et al,
1993). Mann et al. (1984) reported that chronic administration
of agonist analogues of GnRH induced a desensitization of the
pituitary gonadotroph in rhesus monkeys. These authors also
reported that infusion of a GnRH agonist in newborn rhesus
monkeys suppressed the expected prepubertal increase in LH
and testosterone (Mann et al, 1989). In rats, the postnatal
increase in testosterone could be abolished by treatment with
either GnRH agonist or antagonist (Kolho and Huhtaniemi,
1989). Several studies have also emphasized the relationship
between testosterone and a variety of steroid growth promot¬
ers. It was observed (Fabry et al, 1983, 1984; Jones et al, 1991;
Godfrey et al, 1992) that the pulsatile nature of testosterone
profiles was abolished, testosterone secretion markedly reduced(but not suppressed) and puberty delayed after treatment with
androgen, progestagen or oestrogen alone or in combination.
In the present study, the sharp testosterone decrease observed
in the testosterone-treated group after the end of treatment
confirmed that endogenous testosterone synthesis was at a
prepubertal level.
There are few studies that have examined the effects of
testosterone or GnRH administration on the production
of IGF-I in prepubertal males. Schwarz et al. (1992) observed no
difference in plasma IGF-I profiles between bulls castrated
before puberty (gonadectomy at 108 days of age) and intact
bulls until approximately 250 days of age. In the present trial,
although major inhibition of the secretion of endogenous
testosterone took place during both hormonal treatments, there
was no major alteration in IGF-I profiles during the onset of
puberty in the two treatment groups when compared with the
control group. The aim of the present study was to determine
by which pathways IGF-I was modified by GnRH or testoster¬
one treatment. The first observation in the present trial was
that, contrary to the situation in castrated animals, the inhi¬
bition of endogenous testosterone synthesis in the GnRH- and
testosterone-treated groups was not complete. Testosterone
concentrations could therefore have been sufficient to induce
the IGF-I surge at puberty. However, since testosterone
treatment did not induce an increase in IGF-I, it is possible that
the enzymes necessary to aromatize testosterone to oestradiol,
which is known to induce a growth hormone-induced IGF-I
response in cattle (Breier et al, 1988), are only present at
puberty. Another possibility was suggested by Hobbs et al(1993) who observed different effects of treatment with nan-
drolone and testosterone enanthate on IGF-I synthesis by a
qualitative difference in androgenic potency at the neuroendo¬
crine level, particularly if local 5  -reduction of the androgen
occurs. However, Tenover and Matsumoto (1992) found no
change in either growth hormone or IGF-I values in young
adult men treated with testosterone enanthate for 12 weeks.
Low IGF-I values from day 145 to day 155 in the treated
groups could also indicate that testosterone synthesis was
insufficient to sustain normal IGF production via oestrogen
receptors and stimulation by growth hormone, as reported in
steers by Schwarz et al. (1992). This hypothesis is also
supported by the IGF-I increase noted in the present study
after the physiological induction of a pulsatile testosterone
release in both treatment groups.
IGFs in plasma and most body fluids are complexed with
high-affinity binding proteins (IGFBPs). Numerous studies on
nutritional status or treatment with growth hormone have
clearly demonstrated that IGFBP-3, the predominant IGFBP in
plasma, is relevant to the pharmacokinetics and action of IGF-I,
while there is a negative correlation between IGFBP-2 and
IGF-I concentrations (Cohick et al, 1992; Thissen et al, 1994).
Taking into account this information, the results of our
previous study (Renaville et al, 1993) and the data observed by
Lee et al (1991b) in pigs, the transition from puberty to
maturity in bull calves may be identified by a marked decrease
in IGFBP-2 and by an increase in IGFBP-3.
This is the first report of the use of specific monoclonal
antibodies against bovine IGFBP-2 and IGFBP-3 in immuno¬
blotting to confirm the changes in plasma concentrations of
IGFBP-2 and IGFBP-3 observed by western ligand blotting. As
was observed for IGF-I, plasma concentrations of IGFBP-2 and
IGFBP-3 in treated animals followed the profile reported for the
control group and appeared unaffected by testosterone status.
In conclusion, our study shows that the abolition of the
pubertal rise in plasma testosterone, by treatment with GnRH
or testosterone propionate, does not have a marked effect on
IGF-I or on its plasma-binding proteins (IGFBP-2 and IGFBP-3)
in male calves. However, our results suggest that testosterone
can still stimulate IGF-I synthesis, as observed in both treat¬
ment groups between days 180 and 190, when endogenous
plasma concentrations of testosterone are increased. We there¬
fore consider: (1) that the pubertal androgen surge is not the
major factor responsible for the simultaneous increase in IGF-I
and (2), that testosterone and IGF-I values increase simultane¬
ously, but individually, at the onset of puberty in bulls. Further
investigations are needed to understand the mechanism by
which the synthesis of IGF-I and testosterone are induced at
puberty.
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